164 related articles for article (PubMed ID: 20661919)
1. Use of parenteral iron products and serious anaphylactic-type reactions.
Wysowski DK; Swartz L; Borders-Hemphill BV; Goulding MR; Dormitzer C
Am J Hematol; 2010 Sep; 85(9):650-4. PubMed ID: 20661919
[TBL] [Abstract][Full Text] [Related]
2. On the relative safety of intravenous iron formulations: new answers, new questions.
Chertow GM; Winkelmayer WC
Am J Hematol; 2010 Sep; 85(9):643-4. PubMed ID: 20687100
[No Abstract] [Full Text] [Related]
3. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
4. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity reactions and deaths associated with intravenous iron preparations.
Bailie GR; Clark JA; Lane CE; Lane PL
Nephrol Dial Transplant; 2005 Jul; 20(7):1443-9. PubMed ID: 15855210
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
7. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
Atalay H; Solak Y; Acar K; Govec N; Turk S
Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
[TBL] [Abstract][Full Text] [Related]
8. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
9. Evolution of iv iron compounds over the last century.
Macdougall IC
J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
[TBL] [Abstract][Full Text] [Related]
10. [Anaphylactic reaction after Fe-injection].
Fiechter R; Batschwaroff M; Conen D
Praxis (Bern 1994); 2005 Feb; 94(6):209-12. PubMed ID: 15754533
[TBL] [Abstract][Full Text] [Related]
11. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
12. Benchmarking iron dextran sensitivity: reactions requiring resuscitative medication in incident and prevalent patients.
Walters BA; Van Wyck DB
Nephrol Dial Transplant; 2005 Jul; 20(7):1438-42. PubMed ID: 15840683
[TBL] [Abstract][Full Text] [Related]
13. Update on adverse drug events associated with parenteral iron.
Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
Nephrol Dial Transplant; 2006 Feb; 21(2):378-82. PubMed ID: 16286429
[TBL] [Abstract][Full Text] [Related]
14. Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North America.
Bailie GR; Hörl WH; Verhoef JJ
Arzneimittelforschung; 2011; 61(5):267-75. PubMed ID: 21755809
[TBL] [Abstract][Full Text] [Related]
15. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
16. Differences in the reporting rates of serious allergic adverse events from intravenous iron by country and population.
Bailie GR; Verhoef JJ
Clin Adv Hematol Oncol; 2012 Feb; 10(2):101-8. PubMed ID: 22402351
[TBL] [Abstract][Full Text] [Related]
17. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
Sane R; Baribeault D; Rosenberg CL
Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
[TBL] [Abstract][Full Text] [Related]
18. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
Coyne DW; Adkinson NF; Nissenson AR; Fishbane S; Agarwal R; Eschbach JW; Michael B; Folkert V; Batlle D; Trout JR; Dahl N; Myirski P; Strobos J; Warnock DG;
Kidney Int; 2003 Jan; 63(1):217-24. PubMed ID: 12472786
[TBL] [Abstract][Full Text] [Related]
19. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
[TBL] [Abstract][Full Text] [Related]
20. Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
Trumbo H; Kaluza K; Numan S; Goodnough LT
Drug Saf; 2021 Jan; 44(1):107-119. PubMed ID: 33237523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
